1-2 of 2
Jonathan E. Brammer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma

Available to Purchase
Julio C. Chavez, Francine M. Foss, Basem M. William, Jonathan E. Brammer, Sonali M. Smith, Anca Prica, Jasmine M. Zain, Joseph M. Tuscano, Harsh Shah, Neha Mehta-Shah, Praveen Ramakrishnan Geethakumari, Ben X. Wang, Stephanie Zantinge, Lisa Wang, Ling Zhang, Anmarie Boutrin, Weiguang Zhao, Lily Cheng, Nathan Standifer, Lisa Hewitt, Enowmpey Enowtambong, Weiping Shao, Shringi Sharma, Gianluca Carlesso, Jeffrey A. Moscow, Lillian L. Siu
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1869–1878.
https://doi.org/10.1158/1078-0432.CCR-22-2955
Published: 15 May 2023
View articletitled, Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
Open the PDF for Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study

Available to Purchase
Khoan Vu, Chi-Heng Wu, Chen-Yen Yang, Aaron Zhan, Erika Cavallone, Wade Berry, Pamela Heeter, Laura Pincus, Matthew J. Wieduwilt, Basem M. William, Charalambos Andreadis, Lawrence K. Kaplan, Frank McCormick, Pierluigi Porcu, Jonathan E. Brammer, Weiyun Z. Ai
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (5): 1000–1008.
https://doi.org/10.1158/1078-0432.CCR-19-2152
Published: 02 March 2020
View articletitled, Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study
Open the PDF for Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study in another window
Includes: Supplementary data